ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Hodgkin Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Follicular Lymphoma
Leukemia

Lymphoma trials near Taipei City, TWN:

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma...

Enrolling
High-grade B-cell Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Loncastuximab Tesirine

Phase 1

ADC Therapeutics

Taipei, Taiwan and 13 other locations

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma. It will also determine maximum tolerated dose (MTD) and recomm...

Enrolling
Non-Hodgkin Lymphoma
Drug: CHO-H01
Drug: Lenalidomide

Phase 1, Phase 2

Cho Pharma

Taipei, Taiwan and 8 other locations

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...

Active, not recruiting
Relapsed/Refractory Peripheral T-Cell Lymphoma
Adult T Cell Leukemia/Lymphoma
Drug: Valemetostat Tosylate

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Taipei, Taiwan and 59 other locations

Locations recently updated

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back af...

Enrolling
Relapsed/Refractory Follicular Lymphoma
Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Drug: Lenalidomide
Drug: Odronextamab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Taipei, Taiwan and 169 other locations

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (GOLSEEK-2)

to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma...

Active, not recruiting
Lymphoma, Follicular
Drug: Golcadomide
Drug: Doxorubicin

Phase 2

Celgene
Celgene

Taipei, Taiwan and 56 other locations

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib...

Active, not recruiting
Lymphoma, Mantle-Cell
Drug: Ibrutinib
Drug: Pirtobrutinib

Phase 3

Loxo Oncology
Loxo Oncology

Taipei, Taiwan and 194 other locations

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)

The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib
Drug: Bendamustine

Phase 3

Loxo Oncology
Loxo Oncology

Taipei, Taiwan and 107 other locations

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma

This is an open-label, multiple ascending dose (MAD), phase 1 study in adult patients with relapsed or refractory (R/R) B cell non-Hodgkin lymphoma...

Enrolling
B-cell Non Hodgkin Lymphoma
Drug: SAR448501

Phase 1

Sanofi
Sanofi

Taipei, Taiwan and 15 other locations

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (LEDA)

This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma....

Active, not recruiting
Follicular Lymphoma (FL)
Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.
Other: Corticosteroids and/or Radiation (Bridging therapy)

Phase 3

Novartis
Novartis

Taipei, Taiwan and 29 other locations

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovat...

Enrolling
Untreated Follicular Lymphoma
Drug: R-CHOP
Drug: Surovatamig

Phase 3

AstraZeneca
AstraZeneca

Taipei, Taiwan and 134 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems